PSI ToxSIG Webinar: Beyond the looking glass - Interpreting animal welfare & behaviour by monitoring & assessing mice activity data
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
Our first event of 2014 was a joint event with the RSS, with speakers Ying Yuan and Michael Sweeting.
Joint PSI Pharmaceutical Statistics & Royal Statistical Society (RSS)
Webcast
Chair: James Carpenter, School of Hygiene and Tropical Medicine
Speaker: Ying Yuan, Department of Biostatistics, University of Texas
A Bayesian dose finding design for oncology clinical trials of combinational biological agents
Co-authors: Chunyan Cai, Yuan Ji;
Journal of the Royal Statistical Society: Series C (Applied Statistics), Volume 63, Issue 1, Pages 159–173, January 2014
Abstract | Paper+ | Slides
Speaker: Michael J Sweeting, Department of Public Health and Primary Care, University of Cambridge
Escalation strategies for combination therapy Phase I trials
Co-author: Adrian P Mander;
Pharmaceutical Statistics, Volume 11, Issue 3, Pages 258–266, May/June 2012
Abstract | Paper+ | Slides
Discussant: Tony Sabin, Amgen
+ Papers available to view from March 25th 2014 to April 22nd 2014.
For a flier advertising the event, please click here.
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
Our next journal club features two papers on the topic of Survival Analysis. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.
Hear about potential strategies to handle non-proportional hazards and delayed treatment effects from experts in the field.
As a statistician in the Biostatistics and Programming Department, you will be responsible for the methodological and statistical aspects of projects in early clinical development in order to optimize the early development plan and ensure its coherence.
By joining our company, in this role you will apply your skills and experience in support of developing scientifically based arguments aiming to provide fair accessibility to our company’s drugs and vaccines making a real difference in patient’s lives.
As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.